Dua N, Bhatnagar S, Mishra S, Singhal AK. Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy
Department of Anesthesiology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. Anaesthesia and intensive care
(Impact Factor: 1.3).
Modified radical mastectomy is associated with a relatively high incidence of postoperative nausea and vomiting (PONV). This study was undertaken to evaluate the comparative profile and efficacy of ondansetron and granisetron to prevent PONV after modified radical mastectomy. In a randomized, double-blind, placebo-controlled trial, sixty female patients received ondansetron 4 mg, granisetron 1 mg or saline intravenously just before induction of anaesthesia (n = 20 for each group). A standardized general anaesthetic technique was employed. The incidence of PONV and adverse events were recorded for the first 24h postoperatively. The incidence of PONV was 25% with ondansetron, 20% with granisetron and 70% with saline (P < 0.05, Chi-square test with Yates' correction factor). The incidence of adverse events was comparable among the groups. Ondansetron and granisetron are both effective for reducing the incidence of PONV in female patients undergoing modified radical mastectomy.
Available from: derp.ohsu.edu
[Show abstract] [Hide abstract]
ABSTRACT: This chapter discusses several adverse effects of gastrointestinal drugs. A meta-analysis of 10 randomized controlled trials, involving 450 children, has shown that cisapride has no clinically important benefits or harmful effects in children with gastroesophageal reflux. When granisetron was replaced by dolasetron in some patients receiving chemotherapy, there were no adverse outcomes but a significant cost saving. Dolasetron reduces postoperative vomiting in children aged 2–12 years undergoing strabismus surgery. When alosetron is used for severe irritable bowel syndrome with predominant diarrhea, constipation is the most frequent adverse effect; it occurs in 20–30% of patients in clinical trials. Empirical treatment with a proton pump inhibitor is a less effective strategy than first establishing Helicobacter pylori status and eradicating appropriately before starting proton pump inhibitor therapy only in those who are Helicobacter pylori negative. Pantoprazole 40 mg/day and omeprazole MUPS 40 mg/day were equally efficacious in patients with moderate to severe reflux esophagitis in a randomized, double-blind, parallel-group, international, multicenter study.
[Show abstract] [Hide abstract]
ABSTRACT: This prospective, placebo-controlled, double-blinded, and randomized study was undertaken to compare the efficacy of granisetron, droperidol, and combinations of granisetron with droperidol or dexamethasone on postoperative nausea and vomiting in patients undergoing general anesthesia for cesarean section. Patients (n = 150) who were scheduled for cesarean section under general anesthesia were randomly assigned to one of the five groups: physiological saline 5 ml in Group A, granisetron 40 microg/kg + dexamethasone 8 mg in Group B, granisetron 40 microg/kg + droperidol 1.25 mg in Group C, droperidol 1.25 mg in Group D, and granisetron 40 microg/kg in Group E were administered intravenously after clamping of the fetal umbilical cord. Postoperative nausea and vomiting was observed for 024 h after the anesthesia. Cesarean sections were all performed under general anesthesia. Postoperative nausea and vomiting was more common in placebo group (56.7%) than the others during the 0-24 h after the anesthesia (p < 0.05). All granisetron groups were more effective than placebo and droperidol groups during the postoperative 3-24 h (p < 0.01). Although this trial lacks statistical power, granisetron alone and combinations with droperidol or dexamethasone were effective similarly. All treatment groups, except droperidol during the postoperative 3-24 h, were effective for prevention of postoperative nausea and vomiting during the postoperative 0-24 h.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.